38 research outputs found
Graph-based task libraries for robots: generalization and autocompletion
In this paper, we consider an autonomous robot that persists
over time performing tasks and the problem of providing one additional
task to the robot's task library. We present an approach to generalize
tasks, represented as parameterized graphs with sequences, conditionals,
and looping constructs of sensing and actuation primitives. Our approach
performs graph-structure task generalization, while maintaining task ex-
ecutability and parameter value distributions. We present an algorithm
that, given the initial steps of a new task, proposes an autocompletion
based on a recognized past similar task. Our generalization and auto-
completion contributions are eective on dierent real robots. We show
concrete examples of the robot primitives and task graphs, as well as
results, with Baxter. In experiments with multiple tasks, we show a sig-
nicant reduction in the number of new task steps to be provided
Multi-robot task acquisition through sparse coordination
Abstract — In this paper, we consider several autonomous robots with separate tasks that require coordination, but not a coupling at every decision step. We assume that each robot sep-arately acquires its task, possibly from different providers. We address the problem of multiple robots incrementally acquiring tasks that require their sparse-coordination. To this end, we present an approach to provide tasks to mul-tiple robots, represented as sequences, conditionals, and loops of sensing and actuation primitives. Our approach leverages principles from sparse-coordination to acquire and represent these joint-robot plans compactly. Specifically, each primitive has associated preconditions and effects, and robots can con-dition on the state of one another. Robots share their state externally using a common domain language. The complete sparse-coordination framework runs on several robots. We report on experiments carried out with a Baxter manipulator and a CoBot mobile service robot. I
Recommended from our members
Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606.
Alzheimer's disease (AD) is characterized neuropathologically by an abundance of 1) neuritic plaques, which are primarily composed of a fibrillar 42-amino-acid amyloid-β peptide (Aβ), as well as 2) neurofibrillary tangles composed of aggregates of hyperphosporylated tau. Elevations in the concentrations of the Aβ42 peptide in the brain, as a result of either increased production or decreased clearance, are postulated to initiate and drive the AD pathologic process. We initially introduced a novel class of bridged aromatics referred tγ-secretase modulatoro as γ-secretase modulators that inhibited the production of the Aβ42 peptide and to a lesser degree the Aβ40 peptide while concomitantly increasing the production of the carboxyl-truncated Aβ38 and Aβ37 peptides. These modulators potently lower Aβ42 levels without inhibiting the γ-secretase-mediated proteolysis of Notch or causing accumulation of carboxyl-terminal fragments of APP. In this study, we report a large number of pharmacological studies and early assessment of toxicology characterizing a highly potent γ-secretase modulator (GSM), (S)-N-(1-(4-fluorophenyl)ethyl)-6-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-4-methylpyridazin-3-amine (BPN-15606). BPN-15606 displayed the ability to significantly lower Aβ42 levels in the central nervous system of rats and mice at doses as low as 5-10 mg/kg, significantly reduce Aβ neuritic plaque load in an AD transgenic mouse model, and significantly reduce levels of insoluble Aβ42 and pThr181 tau in a three-dimensional human neural cell culture model. Results from repeat-dose toxicity studies in rats and dose escalation/repeat-dose toxicity studies in nonhuman primates have designated this GSM for 28-day Investigational New Drug-enabling good laboratory practice studies and positioned it as a candidate for human clinical trials
Design considerations for workflow management systems use in production genomics research and the clinic
Abstract The changing landscape of genomics research and clinical practice has created a need for computational pipelines capable of efficiently orchestrating complex analysis stages while handling large volumes of data across heterogeneous computational environments. Workflow Management Systems (WfMSs) are the software components employed to fill this gap. This work provides an approach and systematic evaluation of key features of popular bioinformatics WfMSs in use today: Nextflow, CWL, and WDL and some of their executors, along with Swift/T, a workflow manager commonly used in high-scale physics applications. We employed two use cases: a variant-calling genomic pipeline and a scalability-testing framework, where both were run locally, on an HPC cluster, and in the cloud. This allowed for evaluation of those four WfMSs in terms of language expressiveness, modularity, scalability, robustness, reproducibility, interoperability, ease of development, along with adoption and usage in research labs and healthcare settings. This article is trying to answer, which WfMS should be chosen for a given bioinformatics application regardless of analysis type?. The choice of a given WfMS is a function of both its intrinsic language and engine features. Within bioinformatics, where analysts are a mix of dry and wet lab scientists, the choice is also governed by collaborations and adoption within large consortia and technical support provided by the WfMS team/community. As the community and its needs continue to evolve along with computational infrastructure, WfMSs will also evolve, especially those with permissive licenses that allow commercial use. In much the same way as the dataflow paradigm and containerization are now well understood to be very useful in bioinformatics applications, we will continue to see innovations of tools and utilities for other purposes, like big data technologies, interoperability, and provenance
On task recognition and generalization in long-term robot teaching
Several research efforts address the challenge of having users incrementally teach or demonstrate a task to a robot. We are interested in an autonomous robot that persists over time and the problem of teaching it an additional task. We believe that the assumption that a user would know all the tasks previously taught to the robot does not hold. We hence investigate the problem of recognizing when a user is teaching a task similar to one the robot already knows and performing task autocompletion. In this extended abstract, we briefly discuss our approach, and report the results of an experiment run with human teachers
Recommended from our members
Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606.
Alzheimer's disease (AD) is characterized neuropathologically by an abundance of 1) neuritic plaques, which are primarily composed of a fibrillar 42-amino-acid amyloid-β peptide (Aβ), as well as 2) neurofibrillary tangles composed of aggregates of hyperphosporylated tau. Elevations in the concentrations of the Aβ42 peptide in the brain, as a result of either increased production or decreased clearance, are postulated to initiate and drive the AD pathologic process. We initially introduced a novel class of bridged aromatics referred tγ-secretase modulatoro as γ-secretase modulators that inhibited the production of the Aβ42 peptide and to a lesser degree the Aβ40 peptide while concomitantly increasing the production of the carboxyl-truncated Aβ38 and Aβ37 peptides. These modulators potently lower Aβ42 levels without inhibiting the γ-secretase-mediated proteolysis of Notch or causing accumulation of carboxyl-terminal fragments of APP. In this study, we report a large number of pharmacological studies and early assessment of toxicology characterizing a highly potent γ-secretase modulator (GSM), (S)-N-(1-(4-fluorophenyl)ethyl)-6-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-4-methylpyridazin-3-amine (BPN-15606). BPN-15606 displayed the ability to significantly lower Aβ42 levels in the central nervous system of rats and mice at doses as low as 5-10 mg/kg, significantly reduce Aβ neuritic plaque load in an AD transgenic mouse model, and significantly reduce levels of insoluble Aβ42 and pThr181 tau in a three-dimensional human neural cell culture model. Results from repeat-dose toxicity studies in rats and dose escalation/repeat-dose toxicity studies in nonhuman primates have designated this GSM for 28-day Investigational New Drug-enabling good laboratory practice studies and positioned it as a candidate for human clinical trials